A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate
This observational, multicenter survey is designed to assess the efficacy of oral ibandronate in adults with breast cancer and metastatic bone disease. Data on the use of ibandronate in clinical practice will be collected from Hungarian patients.
Metastatic Breast Cancer
Change in bone pain according to Visual Analog Scale (VAS) score, From Baseline to the end of 1 year
Compliance with tablet formulation of ibandronate according to Case Report Form (CRF) questionnaire, Up to approximately 1 year|Incidence of adverse events, Up to approximately 1 year
This observational, multicenter survey is designed to assess the efficacy of oral ibandronate in adults with breast cancer and metastatic bone disease. Data on the use of ibandronate in clinical practice will be collected from Hungarian patients.